Kizzi marks the beginning of a center of excellence for the future of medicine

An impressive crowd gathered at the Chiesi Pharmaceutical Group yesterday (November 21) to celebrate the commencement of the long-awaited work on the Center of Excellence for Biotechnology, bringing the future of medicine to Parma.

Guests, including Italy’s Deputy Minister of Business and Industry, Valentino Valentini, were joined to celebrate the commencement of work on the building, the new Italian and international center of excellence for biopharmaceutical production.

The center is expected to open and be fully operational in 2024. The center will specialize in the development and production of active ingredients for Monoclonal antibodies (produced through recombinant DNA technologies starting with one type of immune cell), enzymes, and others proteins.

Chiesi focuses on biological drugs

“The success of Made in Italy is possible thanks to facts such as Chiesi, ranked first among private companies to invest in research and development in Italy: more than 20% of turnover, almost half a billion euros in 2022, and above all the number of patents.

“The Chiesi Group is now focusing on biological drugs including monoclonal antibodies with an investment of €85 million in an international center of excellence in Parma, underscoring the company’s culture of patient focus, innovation and maximum environmental sustainability,” said Valentini.

Chiesi is keen to develop the specialized expertise already in place Italia And he wants to attract fresh talent and technical skills to work from cells to finished drug and packaging for the global market.

Chiesi is keen to develop expertise

Chiesi believes that establishing a Biotechnology Center of Excellence is the necessary response to the challenges it has highlighted pandemicwhich revealed the need to improve the resilience of the healthcare system, including improving sustainability.

Today, only 22% of all new therapies developed worldwide come from European countries, in part due to slow growth in research, development and investment across the region.

Alberto Casey, head of a family business Chiesi groupHe said: “Today, we are proud to present this new Center of Excellence in the presence of local, regional and national institutions. For Chiesi it has always been necessary to invest in research with the aim of making our country and Europe a leader in production and access to innovation. Furthermore, the new Biotechnology Center represents a powerful message of growth for Italy and for the Parma community in particular, where Chiesi was established and where it is still headquartered,”

Emilia-Romagna to compete at the international level

The ceremony, which took place at the production site Chiesi San Leonardo in Parma, where the new one is being built, was also attended by Valentino Valentini, and included Stefano Bonaccini, president of the Emilia-Romagna region, and councilor Vincenzo Cola, mayor of the city. Parma Michele Guerra, President of PharmIndustria Marcello Cattani, and the Group’s senior management.

“Research, innovation and new technologies are the strategic drivers that will enable a region like Emilia-Romagna to compete on an international level now and in the near future. For this reason, the opening of this center is excellent news that will enrich our region with another prestige of excellence in the pharmaceutical field. As an institution, we intend to stand by Entrepreneurial realities that invest in good jobs, innovation and research, providing them with more and more opportunities.

“Beginning with an enriched regional system, with the inauguration on Thursday in the Technopole of Bologna, the European supercomputer Leonardo, the fourth largest computer in the world in terms of computing power, and extraordinary infrastructure, is at the service of Italy and Europe,” said Stefano Bonaccini, President of the Emilia-Romagna region “

Casey’s commitment to research in Italy

The company says that for Italy and Europe to become leaders in terms of raw materials and access to innovation, it is essential that European and national institutions create standards and regulations that are future-proof. Moreover, she said, it is also necessary to start working to maintain a system of strong incentives that encourage scientific progress, technology and innovative pharmaceuticals. To focus on the value delivered to patients and the healthcare system, it is essential to strive towards organizational ecosystems that go beyond notions of evaluating innovation based on technology.

“With the Biotechnology Center, the company intends to absorb its expertise in order to have an efficient research facility that can develop new drugs and facilitate integration with the manufacturing plant in our region. Our goal will not be to compete with companies large multinational, but to become a center of excellence in our molecules.The biotechnology center will not only be advanced in terms of biotechnology;it will also be developed with the same powers as other corporate facilities.By investing in biotechnology, we are investing in the medicine of the future, preparing future healthcare requirements.

The meeting was also an opportunity to celebrate Kizzi’s commitment to research in Italy; Indeed, the group continues to invest in the region, implementing projects that produce value and new highly qualified jobs. The new therapeutic opportunities offered by the Center of Excellence in Biotechnology will allow the company to become a major player in the biopharmaceutical sector, an industry that has been growing continuously for about 10 years.

Leave a Comment